Immunophenotype of proliferating and differentiating MSCs
. | Proliferating MSCs . | HB-EGF-treated MSCs . | Preadipocytes . | Preosteocytes . | Prechondrocytes . |
---|---|---|---|---|---|
CD105 | ++ | ++ | ± | ± | ± |
CD73 | ++ | ++ | ± | ± | ± |
CD106 | ± | ± | ± | ± | ± |
CD29 | ++ | ++ | ± | ± | ± |
CD44 | +++ | +++ | + | + | + |
CD90 | +++ | +++ | + | + | + |
CD45 | - | - | - | - | - |
CD14 | - | - | - | - | - |
CD11c | - | - | - | - | - |
CD123 | - | - | - | - | - |
CD34 | - | - | - | - | - |
CD31 | - | - | - | - | - |
HB-EGF | - | - | - | - | - |
HER-1 | + | - | - | - | - |
HER-4 | - | - | - | - | - |
CD10 | - | - | + | - | - |
CD56 | - | - | - | + | - |
. | Proliferating MSCs . | HB-EGF-treated MSCs . | Preadipocytes . | Preosteocytes . | Prechondrocytes . |
---|---|---|---|---|---|
CD105 | ++ | ++ | ± | ± | ± |
CD73 | ++ | ++ | ± | ± | ± |
CD106 | ± | ± | ± | ± | ± |
CD29 | ++ | ++ | ± | ± | ± |
CD44 | +++ | +++ | + | + | + |
CD90 | +++ | +++ | + | + | + |
CD45 | - | - | - | - | - |
CD14 | - | - | - | - | - |
CD11c | - | - | - | - | - |
CD123 | - | - | - | - | - |
CD34 | - | - | - | - | - |
CD31 | - | - | - | - | - |
HB-EGF | - | - | - | - | - |
HER-1 | + | - | - | - | - |
HER-4 | - | - | - | - | - |
CD10 | - | - | + | - | - |
CD56 | - | - | - | + | - |
MSC immunophenotype have been analyzed by flow cytometry in standard conditions (proliferating cells), after 2-hour incubation with 25 ng/mL HB-EGF, and after culture with differentiation (adipogenic, osteogenic, chondrogenic) media. HB-EGF-treated MSCs lose HER-1 surface expression, which is restored a few hours after removing HB-EGF from the medium (data not shown). Results are expressed as intensity of expression (-, negative; ± weak expression; +, 1 log shift from negative control; ++, 2 log shifts from negative control; +++, 3 log shifts from negative control) and derive from 6 different experiments.